Literature DB >> 498701

Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.

N M Woolhouse, B Andoh, A Mahgoub, T P Sloan, J R Idle, R L Smith.   

Abstract

The alicyclic and aromatic hydroxylation of debrisoquin was studied in Ghanaians. As in a previously studied Caucasian population, the alicyclic 4-hydroxylation of debrisoquin in Ghanaians was polymorphic. Three phenotypes were observed: homozygous extensive metabolizers (58%), heterozygous extensive metabolizers (36%), and homozygous poor metabolizers (6%). In contrast, British Caucasians are primarily monomorphic extensive metabolizers (92%) and homozygous poor metabolizers comprise 8% of the population. Urinary recovery of the drug and its hydroxylated metabolites was significantly less in the Ghanaian subjects. In both Ghanaian and British populations, aromatic hydroxylation producing 5-, 6-, 7-, and 8-hydroxydebrisoquin was shown to parallel the alicyclic 4-hydroxylation of debrisoquin, and thus to be controlled by the same gene locus. Debrisoquin is advocated as a tool for uncovering polymorphism in drug oxidation and its interethnic variations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498701     DOI: 10.1002/cpt1979265584

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer.

Authors:  Chikako Kiyohara; Taro Shirakawa; Julian M Hopkin
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

3.  Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans.

Authors:  J Vincent; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

4.  Inter-subject and ethnic differences in paracetamol metabolism.

Authors:  J A Critchley; G R Nimmo; C A Gregson; N M Woolhouse; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 5.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

6.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

8.  Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution.

Authors:  D B Jack
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.